[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SDC1

Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein Secreted Secreted, exosome Note=Shedding of the ectodomain produces a soluble form.
Domain PF01034 Syndecan domain
Function

Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001523 retinoid metabolic process
GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0002064 epithelial cell development
GO:0006022 aminoglycan metabolic process
GO:0006023 aminoglycan biosynthetic process
GO:0006024 glycosaminoglycan biosynthetic process
GO:0006026 aminoglycan catabolic process
GO:0006027 glycosaminoglycan catabolic process
GO:0006720 isoprenoid metabolic process
GO:0006721 terpenoid metabolic process
GO:0006887 exocytosis
GO:0006979 response to oxidative stress
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009636 response to toxic substance
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0014074 response to purine-containing compound
GO:0016050 vesicle organization
GO:0016055 Wnt signaling pathway
GO:0016101 diterpenoid metabolic process
GO:0017157 regulation of exocytosis
GO:0030203 glycosaminoglycan metabolic process
GO:0031960 response to corticosteroid
GO:0042157 lipoprotein metabolic process
GO:0042476 odontogenesis
GO:0042542 response to hydrogen peroxide
GO:0042692 muscle cell differentiation
GO:0044089 positive regulation of cellular component biogenesis
GO:0045137 development of primary sexual characteristics
GO:0045445 myoblast differentiation
GO:0045921 positive regulation of exocytosis
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0046683 response to organophosphorus
GO:0048545 response to steroid hormone
GO:0048608 reproductive structure development
GO:0048627 myoblast development
GO:0051047 positive regulation of secretion
GO:0051146 striated muscle cell differentiation
GO:0051384 response to glucocorticoid
GO:0051591 response to cAMP
GO:0051592 response to calcium ion
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0060008 Sertoli cell differentiation
GO:0060009 Sertoli cell development
GO:0060070 canonical Wnt signaling pathway
GO:0060627 regulation of vesicle-mediated transport
GO:0061458 reproductive system development
GO:0071971 extracellular exosome assembly
GO:0072001 renal system development
GO:0072073 kidney epithelium development
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0198738 cell-cell signaling by wnt
GO:1901136 carbohydrate derivative catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1902115 regulation of organelle assembly
GO:1902117 positive regulation of organelle assembly
GO:1903532 positive regulation of secretion by cell
GO:1903541 regulation of exosomal secretion
GO:1903543 positive regulation of exosomal secretion
GO:1903551 regulation of extracellular exosome assembly
GO:1903553 positive regulation of extracellular exosome assembly
GO:1990182 exosomal secretion
Molecular Function GO:0001948 glycoprotein binding
GO:0008022 protein C-terminus binding
Cellular Component GO:0005775 vacuolar lumen
GO:0005796 Golgi lumen
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0030055 cell-substrate junction
GO:0043202 lysosomal lumen
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04512 ECM-receptor interaction
hsa04514 Cell adhesion molecules (CAMs)
Reactome R-HSA-1971475: A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1793185: Chondroitin sulfate/dermatan sulfate metabolism
R-HSA-4420332: Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-3560801: Defective B3GAT3 causes JDSSDHD
R-HSA-3560783: Defective B4GALT7 causes EDS, progeroid type
R-HSA-3656253: Defective EXT1 causes exostoses 1, TRPS2 and CHDS
R-HSA-3656237: Defective EXT2 causes exostoses 2
R-HSA-1643685: Disease
R-HSA-3560782: Diseases associated with glycosaminoglycan metabolism
R-HSA-3781865: Diseases of glycosylation
R-HSA-1474244: Extracellular matrix organization
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-2022928: HS-GAG biosynthesis
R-HSA-2024096: HS-GAG degradation
R-HSA-109582: Hemostasis
R-HSA-1638091: Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-6806667: Metabolism of fat-soluble vitamins
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-3000171: Non-integrin membrane-ECM interactions
R-HSA-975634: Retinoid metabolism and transport
R-HSA-162582: Signal Transduction
R-HSA-3000170: Syndecan interactions
R-HSA-2187338: Visual phototransduction
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SDC1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SDC1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24388357Plasma Cell MyelomaCandidate for immunotherapy targetTransfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. However, these retargeted NK-92MI (NK-92MI-scFv) displayed markedly enhanced cytotoxicity against CD138-positive human MM cell lines (RPMI8226, U266 and NCI-H929) and primary MM cells at various effector-to-target ratios (E:T) as compared to the empty vector-transfected NK-92MI (NK-92MI-mock).
16880256Multiple myeloma(IgA, IgD, IgE, IgM, IgG)Promote immunityIn this study, we show that the clonogenicity of several human tumor cell lines and primary tumor cells from myeloma patients is enhanced by their interactions with DCs. Myeloma cells cultured in the presence of DCs have an altered phenotype with an increased proportion of cells lacking terminal plasma cell differentiation marker CD138. DC-tumor interaction also leads to the up-regulation of B cell lymphoma 6 expression in myeloma cells. Effects of DCs on myeloma cells are inhibited by blockade of the receptor activator of NF-kB (RANK)-RANK ligand and B cell-activating factor-APRIL (a proliferation-inducing ligand)-mediated interactions.
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SDC1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SDC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1070.143
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4010.52
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8970.605
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0890.9
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3990.882
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2950.926
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3590.579
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1470.92
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0120.552
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.310.869
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9920.723
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.140.483
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SDC1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SDC1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SDC1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SDC1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SDC1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SDC1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SDC1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSDC1
Namesyndecan 1
Aliases CD138; syndecan; SYND1; syndecan proteoglycan 1; SDC; CD138 antigen; heparan sulfate proteoglycan fibroblast ......
Chromosomal Location2p24.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SDC1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.